129 related articles for article (PubMed ID: 26078796)
1. Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy.
Choi HC; Kim JH; Kim HS; Jung SG; Hwang SM; Ju SB; Yang I
J Cancer; 2015; 6(7):652-7. PubMed ID: 26078796
[TBL] [Abstract][Full Text] [Related]
2. Tumor response assessment by measuring the single largest lesion per organ in patients with advanced non-small cell lung cancer.
Kim HS; Kim JH; Yang I
Lung Cancer; 2014 Sep; 85(3):385-9. PubMed ID: 25074845
[TBL] [Abstract][Full Text] [Related]
3. The assessment of tumor response by measuring the single largest lesion per organ in metastatic tumors: a pooled analysis of previously reported data.
Jang HJ; Cho JW; Park B; Choi HC; Kim HS; Kim JH
J Cancer; 2015; 6(2):169-76. PubMed ID: 25561982
[TBL] [Abstract][Full Text] [Related]
4. Ideal number of target lesions per organ to measure in metastatic colorectal cancer.
Kim HS; Kim JH
Oncol Lett; 2014 Oct; 8(4):1896-1900. PubMed ID: 25202433
[TBL] [Abstract][Full Text] [Related]
5. Tumor response assessment by the single-lesion measurement per organ in small cell lung cancer.
Jung SG; Kim JH; Kim HS; Kim KJ; Yang I
Chin J Cancer Res; 2016 Apr; 28(2):161-7. PubMed ID: 27199513
[TBL] [Abstract][Full Text] [Related]
6. Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis.
Kim JH; Min SJ; Jang HJ; Cho JW; Kim SH; Kim HS
J Cancer; 2015; 6(4):387-93. PubMed ID: 25767610
[TBL] [Abstract][Full Text] [Related]
7. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.
Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466
[TBL] [Abstract][Full Text] [Related]
8. Comparison of RECIST 1.0 and RECIST 1.1 on computed tomography in patients with metastatic colorectal cancer.
Jang HJ; Kim BC; Kim HS; Kim JH; Song HH; Kim JB; Park JJ; Yoon SN; Woo JY; Zang DY
Oncology; 2014; 86(2):117-21. PubMed ID: 24480800
[TBL] [Abstract][Full Text] [Related]
9. Single-lesion measurement per organ for assessing tumor response in advanced gastric cancer.
Kim HS; Kim JW; Kim JH; Choi DR; Han AR; Kim MJ; Kim BC; Zang DY
Oncology; 2015; 88(2):69-75. PubMed ID: 25277674
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review.
Kim JH
Oncotarget; 2016 Mar; 7(12):13680-7. PubMed ID: 26885610
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review.
Kim JH; Kim BJ; Jang HJ; Kim HS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):729-735. PubMed ID: 28780726
[TBL] [Abstract][Full Text] [Related]
12. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K
Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031
[TBL] [Abstract][Full Text] [Related]
13. Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors.
Kim HK; Heo MH; Lee HS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Cancer Chemother Pharmacol; 2017 Sep; 80(3):591-598. PubMed ID: 28733892
[TBL] [Abstract][Full Text] [Related]
14. Adapted Choi response criteria for prediction of clinical outcome in locally advanced gastric cancer patients following preoperative chemotherapy.
Liu K; Li G; Fan C; Zhou C; Li J
Acta Radiol; 2012 Mar; 53(2):127-34. PubMed ID: 22156007
[TBL] [Abstract][Full Text] [Related]
15. The effectiveness of RECIST on survival in patients with NSCLC receiving chemotherapy with or without target agents as first-line treatment.
Zhou T; Zheng L; Hu Z; Zhang Y; Fang W; Zhao Y; Ge J; Zhao H; Zhang L
Sci Rep; 2015 Jan; 5():7683. PubMed ID: 25567662
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis.
Kim HD; Kim BJ; Kim HS; Kim JH
Korean J Intern Med; 2019 May; 34(3):608-617. PubMed ID: 29334722
[TBL] [Abstract][Full Text] [Related]
17. Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Sun JM; Ahn MJ; Park MJ; Yi JH; Kim TS; Chung MJ; Park YH; Ahn JS; Park K
Lung Cancer; 2010 Jul; 69(1):105-9. PubMed ID: 19959251
[TBL] [Abstract][Full Text] [Related]
18. Comparison of RECIST version 1.0 and 1.1 in assessment of tumor response by computed tomography in advanced gastric cancer.
Jang GS; Kim MJ; Ha HI; Kim JH; Kim HS; Ju SB; Zang DY
Chin J Cancer Res; 2013 Dec; 25(6):689-94. PubMed ID: 24385696
[TBL] [Abstract][Full Text] [Related]
19. Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma.
Choi JH; Ahn MJ; Rhim HC; Kim JW; Lee GH; Lee YY; Kim IS
Cancer Res Treat; 2005 Oct; 37(5):290-3. PubMed ID: 19956529
[TBL] [Abstract][Full Text] [Related]
20. RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis.
Litière S; Isaac G; De Vries EGE; Bogaerts J; Chen A; Dancey J; Ford R; Gwyther S; Hoekstra O; Huang E; Lin N; Liu Y; Mandrekar S; Schwartz LH; Shankar L; Therasse P; Seymour L;
J Clin Oncol; 2019 May; 37(13):1102-1110. PubMed ID: 30860949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]